ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 5, 2012
News
GPhA Urges Congress to Move Ahead on Generic-Drug and Biosimilar User Fees
By Patricia Van Arnum
On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.
Ranbaxy Begins Shipping Generic Lipitor From Indian Facility
By Amy Ritter
Ranbaxy Laboratories announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer's Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.
EMA Gets Tough on Conflicts of Interest
By Rose Price
The management board of the European Medicines Agency has introduced a range of new measures to strengthen and extend its conflicts of interest policy for scientific-committee members and experts, as well as for members of the management board.
Week of Apr. 2, 2012: Amgen, AstraZeneca Agree to Codevelop Monoclonal Antibodies; Fujifilm Diosynth Biotechnologies Expands R&D Capabilities at its UK Site; and More
Amgen, AstraZeneca Agree to Codevelop Monoclonal Antibodies; Fujifilm Diosynth Biotechnologies Expands R&D Capabilities at its UK Site; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here